Biotech Co. FibroGen Raises $146M In Upper Range IPO
Anemia treatment developer FibroGen raised $146 million in its initial public offering on Friday after pricing at the higher end of its range, making it among the largest listed biotechs by...To view the full article, register now.
Already a subscriber? Click here to view full article